IndraLab

Statements


| 3

reach
"Furthermore, treatment with the Usp11 inhibitor, mitoxantrone, successfully targeted and inhibited Usp11, thereby alleviating the reduction in MZ B cells in the spleen following total body irradiation."

reach
"87,107,108 Mitoxantrone, a PARPi that targets the USP11 key enzyme that interacts with BRCA2, has been shown to be 40- to 20,000-fold more potent than the current gemcitabine first-line treatment in 2[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"

reach
"Additionally, the type II topoisomerase inhibitor mitoxantrone inhibits USP11 and demonstrates increased progression-free and overall survival in a relapsed T-ALL clinical trial, suggesting that USP11 inhibition can be exploited therapeutically [14, 15]."